Open AccessNursing Skill and Responsibility in Administration of Injection Actilyse
Author(s) -
Mayur Wanjari,
Deeplata Mendhe,
Pratibha Wankhede
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i57b34039
Subject(s) - plasminogen activator , recombinant dna , medicine , complementary dna , glycoprotein , tissue plasminogen activator , pharmacology , activator (genetics) , microbiology and biotechnology , chemistry , biology , gene , biochemistry , receptor
Actilyse can break blood clots that form in the heart, blood arteries, or lungs during a heart attack. This medication is also given to stroke patients to improve recovery and reduce the likelihood of impairment. Recombinant DNA technology was used to create Activase, a tissue plasminogen activator. It is a sterile, purified glycoprotein of 527 amino acids. It is made by combining complementary DNA (cDNA) from a human melanoma cell line with the natural human tissue-type plasminogen activator. After reconstitution with Sterile Water for Injection, USP, Activase is a sterile, white to off-white lyophilized powder for intravenous injection.